Centre bans 16 Fixed Dose Combination (FDC) drugs over safety and efficacy concerns

In a decisive move to protect public health, India's Ministry of Health and Family Welfare has immediately banned the manufacture, sale, and distribution of 16 Fixed Dose Combination (FDC) drugs. This urgent action, effective from Saturday, June 20, 2026, targets drug combinations found to lack scientific justification and potentially endanger patient safety, reinforcing the government's push for safe and evidence-based medicine use across the country. The banned list includes everything from certain pain-relief and antispasmodic medicines to dermatological preparations and antibiotic-based formulations, highlighting a broad sweep of products deemed irrational. This isn't the first time India has cracked down on FDCs; similar significant bans occurred in 2016 and 2018, often following Supreme Court directives for rigorous review. These 'irrational' combinations combine multiple active ingredients without clear therapeutic benefits over individual drugs and can even contribute to serious health concerns like antibiotic resistance. The latest prohibition follows detailed scientific evaluation by an Expert Committee, constituted by the Drugs Technical Advisory Board (DTAB), which meticulously assessed the safety and efficacy of these drug cocktails. The immediate ramifications will be felt across the Indian pharmaceutical industry, with manufacturers required to cease production and recall existing stocks. This ban sends a clear message: regulatory scrutiny on drug formulations is intensifying, pushing companies towards more rigorous testing and evidence-based practices. For patients, while some familiar medications may no longer be available, the long-term benefit is a safer drug market and a stronger commitment to the rational use of medicines, urging continuous vigilance from both regulators and consumers in India's vast healthcare landscape.